Analysts expect Amgen Inc. (NASDAQ:AMGN) to report earnings per share (EPS) of $3.09 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Amgen’s earnings, with the lowest EPS estimate coming in at $3.01 and the highest estimate coming in at $3.19. Amgen posted earnings of $2.84 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 8.8%. The company is expected to issue its next quarterly earnings results on Wednesday, July 26th.

According to Zacks, analysts expect that Amgen will report full year earnings of $12.39 per share for the current year, with EPS estimates ranging from $12.07 to $12.81. For the next fiscal year, analysts anticipate that the company will report earnings of $12.57 per share, with EPS estimates ranging from $11.90 to $13.13. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Amgen.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.00 by $0.15. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The firm had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the firm earned $2.90 earnings per share. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the stock. Vetr cut shares of Amgen from a “buy” rating to a “hold” rating and set a $179.46 price objective for the company. in a report on Monday, February 27th. Goldman Sachs Group, Inc. (The) decreased their price objective on shares of Amgen from $208.00 to $202.00 and set a “conviction-buy” rating for the company in a report on Monday, March 20th. Jefferies Group LLC reiterated a “hold” rating and issued a $180.00 price objective on shares of Amgen in a report on Monday, May 22nd. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price objective on shares of Amgen in a report on Wednesday, February 22nd. Finally, Cann reiterated a “positive” rating and issued a $189.00 price objective on shares of Amgen in a report on Wednesday, March 15th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $185.49.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/06/14/amgen-inc-amgn-expected-to-announce-earnings-of-3-09-per-share.html.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of AMGN. Price T Rowe Associates Inc. MD raised its stake in Amgen by 9.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 2,978,125 shares of the medical research company’s stock valued at $496,781,000 after buying an additional 256,691 shares during the last quarter. Piedmont Investment Advisors LLC purchased a new stake in Amgen during the third quarter valued at $33,136,000. Whalerock Point Partners LLC purchased a new stake in Amgen during the third quarter valued at $1,018,000. Ashburton Jersey Ltd purchased a new stake in Amgen during the third quarter valued at $752,000. Finally, TrueNorth Inc. purchased a new stake in Amgen during the third quarter valued at $1,032,000. 78.86% of the stock is owned by institutional investors.

Shares of Amgen (NASDAQ AMGN) traded up 0.41% on Wednesday, reaching $165.10. The company had a trading volume of 2,594,842 shares. Amgen has a 52-week low of $133.64 and a 52-week high of $184.21. The company has a 50 day moving average price of $160.18 and a 200 day moving average price of $160.69. The stock has a market capitalization of $121.41 billion, a PE ratio of 15.68 and a beta of 1.37.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Get a free copy of the Zacks research report on Amgen (AMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.